NCT05789901 The MARVIN Chatbots to Provide Information for Different Health Conditions
| NCT ID | NCT05789901 |
| Status | Recruiting |
| Phase | — |
| Sponsor | McGill University Health Centre/Research Institute of the McGill University Health Centre |
| Condition | HIV Infections |
| Study Type | INTERVENTIONAL |
| Enrollment | 400 participants |
| Start Date | 2024-03-01 |
| Primary Completion | 2033-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 400 participants in total. It began in 2024-03-01 with a primary completion date of 2033-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This research is a continuation of a usability study with the MARVIN chatbot. The investigators aim to adapt the MARVIN chatbot to open it to other health domains (e.g. breast cancer) and populations (e.g. pharmacists). Therefore, this protocol constitutes a master research protocol that will englobe different research projects with individual chatbots. The investigators adopt an adaptive platform trial design, which will allow flexibility in handling multiple interventions adapted to different populations while retaining the characteristics of a platform trial design allowing early withdrawal of ineffective trial arms based on interim data (implementation outcomes) and introduction of new trial arms.
Eligibility Criteria
Inclusion Criteria for all objectives: * being 14 years or older; * being fluent in English and/or French; * being able to understand the requirements of study participation and provide informed consent during the duration of the study; * having access to a smartphone, tablet, or computer at home/at workplace; * having access to an internet connection at home or data plan on their device. Inclusion Criteria Specific to objectives 2 and 3: * accept to use a Facebook Messenger-based Chatbot; * accept to use or create a personal Facebook account; * accept Facebook's privacy and data security policies. Exclusion Criteria: * not meeting the inclusion criteria * any reason, in the opinion of the investigator, which would make the candidate inappropriate for participation in an investigative study involving a chatbot (e.g., cognitive deficit)
Contact & Investigator
Bertrand Lebouché, MD
PRINCIPAL INVESTIGATOR
McGill University Health Centre/Research Institute of the McGill University Health Centre
Frequently Asked Questions
Who can join the NCT05789901 clinical trial?
This trial is open to participants of all sexes, aged 14 Years or older, studying HIV Infections. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05789901 currently recruiting?
Yes, NCT05789901 is actively recruiting participants. Contact the research team at bertrand.lebouche@mcgill.ca for enrollment information.
Where is the NCT05789901 trial being conducted?
This trial is being conducted at Montreal, Canada, Montreal, Canada.
Who is sponsoring the NCT05789901 clinical trial?
NCT05789901 is sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre. The principal investigator is Bertrand Lebouché, MD at McGill University Health Centre/Research Institute of the McGill University Health Centre. The trial plans to enroll 400 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.